Gavin Wood - 20 May 2022 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Role
Chief Financial Officer
Signature
/s/ Gavin Wood
Issuer symbol
ADAP
Transactions as of
20 May 2022
Net transactions value
+$11,326
Form type
4
Filing time
23 May 2022, 21:00:33 UTC
Previous filing
13 Jan 2022
Next filing
17 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADAP Ordinary Shares with a nominal value of GBP0.001 per share Purchase $11,326 +39,000 +68% $0.2904 96,000 20 May 2022 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.
F2 The 39,000 ordinary shares reported in Column 4 are represented by 6,500 ADSs.
F3 The price reported in Column 4 of $0.2904 per ordinary share is derived from the purchase price paid on May 20, 2022 of $1.7423 per ADS divided by six.
F4 The 96,000 ordinary shares reported in Column 5 include 57,000 ordinary shares represented by 9,500 ADSs owned by Mr. Wood prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Wood.